Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Innate Pharma SA ( (FR:IPH) ) has provided an update.
Innate Pharma has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference, scheduled for January 13-16, 2025, in San Francisco. This participation, including a presentation by CEO Jonathan Dickinson and other executives, signifies the company’s continued engagement with key industry stakeholders and provides a platform to highlight its innovative cancer immunotherapy developments, potentially influencing its market positioning and stakeholder confidence.
More about Innate Pharma SA
Innate Pharma S.A. is a global, clinical-stage biotechnology company focused on developing immunotherapies for cancer patients. The company utilizes innovative approaches such as monoclonal antibodies, multi-specific NK Cell Engagers through its ANKET® platform, and Antibody Drug Conjugates. Innate Pharma’s portfolio includes proprietary programs like lacutamab for advanced T cell lymphomas, monalizumab with AstraZeneca for non-small cell lung cancer, and several ANKET® candidates targeting various tumors. The company collaborates with biopharmaceutical entities such as Sanofi and AstraZeneca to enhance innovation in research and development.
YTD Price Performance: 2.11%
Average Trading Volume: 1,212
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $172.5M
See more data about IPH stock on TipRanks’ Stock Analysis page.
